@article {813,
	title = {The integrated genomic surveillance system of Andalusia (SIEGA) provides a One Health regional resource connected with the clinic.},
	journal = {Sci Rep},
	volume = {14},
	year = {2024},
	month = {2024 Aug 19},
	pages = {19200},
	abstract = {<p>The One Health approach, recognizing the interconnectedness of human, animal, and environmental health, has gained significance amid emerging zoonotic diseases and antibiotic resistance concerns. This paper aims to demonstrate the utility of a collaborative tool, the SIEGA, for monitoring infectious diseases across domains, fostering a comprehensive understanding of disease dynamics and risk factors, highlighting the pivotal role of One Health surveillance systems. Raw whole-genome sequencing is processed through different species-specific open software that additionally reports the presence of genes associated to anti-microbial resistances and virulence. The SIEGA application is a Laboratory Information Management System, that allows customizing reports, detect transmission chains, and promptly alert on alarming genetic similarities. The SIEGA initiative has successfully accumulated a comprehensive collection of more than 1900 bacterial genomes, including Salmonella enterica, Listeria monocytogenes, Campylobacter jejuni, Escherichia coli, Yersinia enterocolitica and Legionella pneumophila, showcasing its potential in monitoring pathogen transmission, resistance patterns, and virulence factors. SIEGA enables customizable reports and prompt detection of transmission chains, highlighting its contribution to enhancing vigilance and response capabilities. Here we show the potential of genomics in One Health surveillance when supported by an appropriate bioinformatic tool. By facilitating precise disease control strategies and antimicrobial resistance management, SIEGA enhances global health security and reduces the burden of infectious diseases. The integration of health data from humans, animals, and the environment, coupled with advanced genomics, underscores the importance of a holistic One Health approach in mitigating health threats.</p>},
	keywords = {Animals, Drug Resistance, Bacterial, Genome, Bacterial, Genomics, Humans, One Health, Virulence Factors, Whole Genome Sequencing},
	issn = {2045-2322},
	doi = {10.1038/s41598-024-70107-0},
	author = {Casimiro-Soriguer, Carlos S and Perez-Florido, Javier and Robles, Enrique A and Lara, Mar{\'\i}a and Aguado, Andrea and Rodr{\'\i}guez Iglesias, Manuel A and Lepe, Jose A and Garc{\'\i}a, Federico and P{\'e}rez-Alegre, M{\'o}nica and And{\'u}jar, Elo{\'\i}sa and Jim{\'e}nez, Victoria E and Camino, Lola P and Loruso, Nicola and Ameyugo, Ulises and Vazquez, Isabel Mar{\'\i}a and Lozano, Carlota M and Chaves, J Alberto and Dopazo, Joaquin}
}
@article {725,
	title = {Implementing Personalized Medicine in COVID-19 in Andalusia: An Opportunity to Transform the Healthcare System.},
	journal = {J Pers Med},
	volume = {11},
	year = {2021},
	month = {2021 May 26},
	abstract = {<p>The COVID-19 pandemic represents an unprecedented opportunity to exploit the advantages of personalized medicine for the prevention, diagnosis, treatment, surveillance and management of a new challenge in public health. COVID-19 infection is highly variable, ranging from asymptomatic infections to severe, life-threatening manifestations. Personalized medicine can play a key role in elucidating individual susceptibility to the infection as well as inter-individual variability in clinical course, prognosis and response to treatment. Integrating personalized medicine into clinical practice can also transform health care by enabling the design of preventive and therapeutic strategies tailored to individual profiles, improving the detection of outbreaks or defining transmission patterns at an increasingly local level. SARS-CoV2 genome sequencing, together with the assessment of specific patient genetic variants, will support clinical decision-makers and ultimately better ways to fight this disease. Additionally, it would facilitate a better stratification and selection of patients for clinical trials, thus increasing the likelihood of obtaining positive results. Lastly, defining a national strategy to implement in clinical practice all available tools of personalized medicine in COVID-19 could be challenging but linked to a positive transformation of the health care system. In this review, we provide an update of the achievements, promises, and challenges of personalized medicine in the fight against COVID-19 from susceptibility to natural history and response to therapy, as well as from surveillance to control measures and vaccination. We also discuss strategies to facilitate the adoption of this new paradigm for medical and public health measures during and after the pandemic in health care systems.</p>},
	issn = {2075-4426},
	doi = {10.3390/jpm11060475},
	author = {Dopazo, Joaquin and Maya-Miles, Douglas and Garc{\'\i}a, Federico and Lorusso, Nicola and Calleja, Miguel {\'A}ngel and Pareja, Mar{\'\i}a Jes{\'u}s and L{\'o}pez-Miranda, Jos{\'e} and Rodr{\'\i}guez-Ba{\~n}o, Jes{\'u}s and Padillo, Javier and T{\'u}nez, Isaac and Romero-G{\'o}mez, Manuel}
}
